MedPath

Examination concerning dosage of dexamethasone when Fosaprepitant and Palonosetron are used together for nausea and vomiting induced chemotherapy for head and neck cancer.

Not Applicable
Conditions
head and neck cancer
Registration Number
JPRN-UMIN000008080
Lead Sponsor
Hiroshima University Hospital Department of Otorhinolaryngology Head and Neck Surgery
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

(a) Vomiting prior to chemotherapy within 24hours (b) They have the factor (tumor of the brain, street trouble of the gut, ulcus pepticum of briskness, and cerebral metastasis, etc.) that nausea and vomiting are caused besides the cancer chemotherapy (c) They have an associated symptom (ex infectious disease) patient who cannot administer dexamethasone. (d) judged by the investigator to be inappropriate for this study (e) pimozide is being administered.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Complete response rate of vomiting within 120hours from cisplatin administration
Secondary Outcome Measures
NameTimeMethod
(a)Complete response rate of vomiting within 24hours,and 24-120 hours from cisplatin administration. (b)Level of nausea (c)Level of anorexia (d)The proportion of patients receiving rescue medication. (e)Evaluation of nausea and vomiting of each course on 10 point scale. (f)adverse event
© Copyright 2025. All Rights Reserved by MedPath